key: cord-0772567-v4tfkhf6
authors: Jiménez-Brítez, Gustavo; Ruiz, Pablo; Soler, Xavier
title: Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
date: 2020-07-09
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2020.07.001
sha: 9a7e58164cf8e033005b26a22c6b0e27aa6171b7
doc_id: 772567
cord_uid: v4tfkhf6

nan

The cytokine storms (CS) mediated by overproduction of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19 (1) In previous studies, severe patients that have been hospitalized for COVID-19 have had laboratory results that show an increased level of cytokines, specifically interleukin 6 (IL-6).

Tocilizumab is a recombinant humanized monoclonal antibody that has an antagonist effect on the IL-6 receptor, and could play a role in treatment for severely ill patients with COVID-19 (2) .

Corticosteroids such as methylprednisolone (MP) are the conventional agents used to treat CS, but usually are related with risk of side effects, the most common the secondary infection.

There are observational studies on the frontline in China and Italy that suggest the use of J o u r n a l P r e -p r o o f methylprednisolone was associated with better clinical outcomes in severe patients with COVID-19 pneumonia (3, 4) .

This was a single centre observational study. We report the outcomes of patients tretaed with tocilizumab plus glucocorticoids in severe and critical severe COVID-19 patients between March 26 and April 17, 2020 in a Intensive Care Unit (ICU) Hospital in Barcelona, Spain. We included patients with high suspicion of CS (persisten fever, increase in inflammatory parameters (CPR, D dimer, ferritine), and excluded patients with confirmed bacterial superinfection at the start of the tretament. Methylprednisolone were adminstered 1mg/kp/day during the inflammatory phase. Afther that, decreasing doses were administered.

Twenty five patients (14 males and 11 females) with COVID-19 were included in this study. The characteristics of patients, status, laboratory and clinical outcomes are summarized in Table 1 .

The media age of the patients was 62,4 years. Eight (32%) patients were severe ill, and 17 were critical severe ill (68%), 15 of them with invasive mechanical ventilation, 2 with non invasive ventilation and 8 with high doses of oxigen (O2 mask more than 50% FiO2, or high flow oxygen) at the start of the treatment. The time that the anti-inflammatory treatment with tocilizumab was started since the hospital admission was variable among patients, the treatment were started earlier than those who died (7,6 ± 5 vs. 13,6 ± 7,7 days; p: 0,03)

In our study we observed a significant decrease in fever, CPR, D-dimer, ferritine, and an increase in the total number of lymphocytes at 72 hs after ther start the anti-inflammatory treatment in critical COVID patients.

The reported mortality in critically ill patients infected by COVID 19 is high between 18-66% (5).

For this reason, pharmacological strategies should be sought to mitigate the inflammatory phase. Although data from several ongoing randomized, controlled trials will soon provide more evidence regarding the different treatments, the outcomes observed in this report specifically the improvements in the inflamamatory parameter, with a 72% of the patients discharge from the hospitalization and overall mortality of 20%, suggest that tocilizumab glucocorticoids appears to be an effective treatment option in COVID-19 patients to attenuate the CS. 

Why tocilizumab could be an effective treatment for severe COVID-19?

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

National institute for the infectious diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management

Interpretation of "Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5

mg/dl) basal, mean ± SD CPR, (mg/dl) 72hs, mean ± SD Lymphocytes (mm3)

/ml), basal, mean ± SD, basal

72h, mean ± SD, basal D-dimer (μg/l), mean ± SD